Original articles

Valvular heart disease

Incidence and risk factors of early thromboembolic events after mechanical heart valve replacement in patients treated with intravenous unfractionated heparin

N Allou¹, P Piednoir¹, C Berroëta¹, S Provenchère¹, H Ibrahim¹, G Baron², P Montravers¹, B Iung³, I Philip¹, N Ajzenberg⁴

¹ Département d’Anesthésie-Réanimation-Chirurgicale, Groupe Hospitalier Bichat-Claude Bernard (AP-HP), Faculté Xavier Bichat (Université Paris 7), Paris, France
² Département d’Epidémiologie, Biostatistique et Recherche Clinique, Groupe Hospitalier Bichat-Claude Bernard (AP-HP), Faculté Xavier Bichat (Université Paris 7), Paris, France
³ Service de Cardiologie, Groupe Hospitalier Bichat-Claude Bernard (AP-HP), Faculté Xavier Bichat (Université Paris 7), Paris, France
⁴ Laboratoire d’Hémostase et d’Immunologie, Groupe Hospitalier Bichat-Claude Bernard (AP-HP), Faculté Xavier Bichat (Université Paris 7), Paris, France

^{Correspondence to} Dr I Philip, Département d’Anesthésie-Réanimation-Chirurgicale, Hôpital Bichat, 46 rue Henri Huchard, 75877 Paris, Cedex 18, France; ivan.philip{at}bch.aphp.fr

Objective: To evaluate the incidence and risk factors, including timing and intensity of anticoagulation, of early thromboembolic events (TE) after mechanical heart valve replacement (MHVR) in patients treated by intravenous unfractionated heparin (IVUH).

Design: Prospective observational study, conducted between December 2005 and May 2007.

Setting: Haemostasis laboratory, surgical intensive care unit and ward in a university hospital.

Patients: Three hundred consecutive patients undergoing MHVR. Mitral or double MHVR was performed in 149 patients, and aortic MHVR in 151 patients. Postoperative anticoagulation was achieved with continuous IVUH according to a standardised protocol. The timing of efficient anticoagulation was recorded for each patient.

Main outcome measures: The end point was the occurrence of any arterial TE from day 1 to day 30. Transoesophageal echocardiography was systematically performed after mitral MHVR.

Results: Early TE occurred in 22 patients (14.8%; 95% CI 9% to 20%) after a mitral or double MHVR and in two patients (1.3%; 95% CI 0% to 3%) after an aortic MHVR (p = 0.005). After adjustment for diabetes mellitus (adjusted OR (aOR) = 3.3; 95% CI 1.0 to 10.9, p = 0.049), and for the presence of predisposing factors (heparin-induced thrombocytopenia or bradycardia requiring definitive pacemaker implantation) (aOR = 12.8; 95% CI 3.1 to 53.3, p<0.001), effective anticoagulation on day 3 was a protective factor (aOR = 0.28; 95% CI 0.1 to 0.8, p = 0.018) for early TE after mitral MHVR.

Conclusions: Despite the use of IVUH, the rate of early TE after mitral MHVR remained elevated. These results suggest that early effective anticoagulation is required after mitral MHVR, since inappropriate anticoagulation on day 3 was significantly associated with early TE.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Managing heparin anticoagulation in patients with prosthetic cardiac valves: balancing the risk

Abdul Shlebak and Iqbal Malik
Heart 2009 95: 1643-1645. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Shlebak, A., Malik, I. (2009). Managing heparin anticoagulation in patients with prosthetic cardiac valves: balancing the risk. Heart 95: 1643-1645 [Full Text]